I’m seeing some “free market” simps defending Nature’s 12k open access fees. Guess it’s time to bring this back around.

I think these are one of the most important points in understanding management of CS. I also believe this why #ECLS-SHOCK trial was negative (most pts didn‘t benefit from ECLS as lactate clearance was identical between groups). Focus on identifying the deteriorating pts❗️⚠️

81y/o w admitted with decompensated heart failure. Initial TTE report stated no sign. valvular abnormalities, but Echo quality was poor. Great example how valuable a second look can be. If you can‘t tell what’s going on, seek help or reschedule #echofirst #TTE #heartfailure

Wow. Even in an open label trial, PCI in the “perfect” patient (amenable anatomy + viability) did not result in QOL improvements at one year over simple tablets. REVIVED continues to shock the cardiology community Link jacc.org/doi/10.1016/j.…

In the ORBITA-STAR trial, a n-of-1, placebo-controlled study in patients undergoing single-vessel PCI, participants underwent 4 episodes (60 seconds each) of low-pressure balloon occlusion, randomly paired with 4 episodes of placebo inflation. Following each episode, patients

29 y/o male referred to #CMR for susp of atrial mass. Turned out to be #Thrombus stuck somewhere between rete chiari and coronary sinus ostium #whyCMR #CMRfirst He had a #DVT 2 weeks prior and is on anticoagulation Sara Moscatelli Robert Manka @GTersalv

Case of the week: the 48 y/o caucasian male is referred for the susp of #hcm with a ❤️ septum um 15mm on #echocardiography we referred him to CMR. Fam Hx is neg Native T1 790ms (1.5T Siemens Aera) ‼️ In Haste the liver appeared normal What is the diagnosis? 🧠 #CMR #whyCMR

74y/o male diagnosed with #HFpEF 3 y ago #DPD #spect was scheduled after severe progr LVH became obvious. The #CMR LGE PSIR has all the hallmarks of cardiac #amyloidosis ECV>50% I wonder why we wait so long to look for amyloid in older adults with HFpEF… #WhyCMR #CMRfirst

I agree that this is an important piece if the puzzle, but the study lacks a proper control group. We have no idea what #SAVR would do in similar patients. Maybe better, maybe similar, maybe worse ❓ We will need better data before we can draw any conclusions. Gregorio Tersalvi

It is a great achievement, nevertheless it is sad to see that academia is often just a paper, citation and impact counting profession Shouldn‘t we all rather ask for one good paper that has a meaning (ie changes clinical practice) instead? Gregorio Tersalvi Wilfried Mullens Robert Manka

Davide Capodanno No difference in CV death or all-cause death. No difference in all cause hospitalization. 68 fewer HHF but 34 fewer all cause hospitalization which means there are 34 excess non-HHF. This is a lower risk cohort c/w MITRA-FR with lower EOA, yet PEP was positive! Why?

Davide Capodanno What are we to make of a trial with 36 quintuple composite outcome, wide NI margin and fewer observed PEP events than assumed?

Totally agree. LGE patterns and clinical context are key.